We use cookies to improve your experience. By your continued use of this site you accept such use.
MiGenTra
Source: MiGenTra |

SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries

This landmark MOU marks a significant step towards ensuring national health security and achieving biomanufacturing autonomy in Saudi Arabia

SaudiVax, a leading biopharmaceutical company in Saudi Arabia, Minapharm Pharmaceuticals, a premier biopharmaceutical company and global provider of proprietary technologies headquartered in Egypt with multiple subsidiaries in Berlin, and MiGenTra GmbH (https://www.MiGenTra.com/), a healthcare transforming medicines company headquartered in Berlin, today announced the signing on 26th September 2023 of a Memorandum…

MiGenTra

  • Multimedia content

  • Images (1)
    • Participants Dosed on Adessia® in Germany in a Phase 1 Trial
  • All (1)
Source: MiGenTra |

Participants Dosed on Adessia® in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa

This follows a prior announcement made by Minapharm Pharmaceuticals on February 13, 2023 reporting that said Phase 1 trial received unconditional approval from the Paul-Ehrlich Institut (PEI)

MiGenTra (www.Migentra.com), a Berlin-based healthcare transforming company, reported today that the first participants in a Phase 1 clinical trial for Minapharm Pharmaceuticals (www.Minapharm.com) adalimumab biosimilar candidate (brand name: Adessia®) were dosed on February 24, 2023 in Germany. This follows a prior announcement made by Minapharm Pharmaceuticals on February 13, 2023 reporting…

MiGenTra
Source: MiGenTra |

Bioventure, Minapharm Pharmaceuticals and MiGenTra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa

According to the agreement, Minapharm Pharmaceuticals and MiGenTra GmbH will share responsibilities in the Territory to file, launch and commercialize Alvotech's portfolio of licensed biosimilars once approved

Bioventure, a Dubai-based pharmaceutical company, Minapharm Pharmaceuticals, a Cairo-based pharmaceutical company, and MiGenTra GmbH (https://www.MiGenTra.com), a Berlin-based pharmaceutical company, announced today the signing of an exclusive license agreement for the commercialization of multiple biosimilar candidates developed and manufactured by Alvotech, in Egypt and eighteen additional countries in Africa and the…